These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

510 related items for PubMed ID: 6099390

  • 1. Effect of dietary sodium on angiotensin-converting enzyme (ACE) inhibition and the acute hypotensive effect of enalapril (MK-421) in essential hypertension.
    Jackson B, Cubela R, Johnston CI.
    J Hypertens; 1984 Aug; 2(4):371-7. PubMed ID: 6099390
    [Abstract] [Full Text] [Related]

  • 2. Correlation between angiotensin converting enzyme inhibition and the acute hypotensive response to MK 421 in essential hypertension.
    Jackson B, McGrath BP, Johnston CI.
    Clin Exp Pharmacol Physiol Suppl; 1982 Aug; 7():99-104. PubMed ID: 6291832
    [Abstract] [Full Text] [Related]

  • 3. Relationship of antihypertensive effect of enalapril to serum MK-422 levels and angiotensin converting enzyme inhibition.
    Johnston CI, Jackson B, McGrath B, Matthews G, Arnolda L.
    J Hypertens Suppl; 1983 Oct; 1(1):71-5. PubMed ID: 6100611
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Enalapril and lisinopril in renovascular hypertension--antihypertensive and hormonal effects of two new angiotensin-converting-enzyme (ACE) inhibitors. A preliminary report.
    Karlberg BE, Fyhrquist F, Grönhagen-Riska C, Tikkanen I, Ohman KP.
    Scand J Urol Nephrol Suppl; 1984 Oct; 79():103-6. PubMed ID: 6089307
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of angiotensin I-converting enzyme with S 9490: biochemical effects, interspecies differences, and role of sodium diet in hemodynamic effects.
    Laubie M, Schiavi P, Vincent M, Schmitt H.
    J Cardiovasc Pharmacol; 1984 Oct; 6(6):1076-82. PubMed ID: 6084763
    [Abstract] [Full Text] [Related]

  • 7. Vasoactive peptides and hypertension: role of angiotensin converting enzyme.
    Johnston CI, Iansek R, Millar JA, McGrath BP, Matthews PG.
    Aust N Z J Med; 1981 Oct; 11(Suppl 1):59-63. PubMed ID: 6266379
    [Abstract] [Full Text] [Related]

  • 8. Effects of enalapril maleate on blood pressure, renin-angiotensin-aldosterone system, and peripheral sympathetic activity in essential hypertension.
    Cerasola G, Cottone S, D'Ignoto G, Grasso L, Carone MB, Carapelle E, Contorno A.
    Clin Ther; 1987 Oct; 9(4):390-9. PubMed ID: 3038326
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response?
    van den Meiracker AH, Man in 't Veld AJ, Admiraal PJ, Ritsema van Eck HJ, Boomsma F, Derkx FH, Schalekamp MA.
    J Hypertens; 1992 Aug; 10(8):803-12. PubMed ID: 1325513
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Enalaprilat: an intravenous substitute for oral enalapril therapy. Humoral and pharmacokinetic effects.
    Reams GP, Lal SM, Whalen JJ, Bauer JH.
    J Clin Hypertens; 1986 Sep; 2(3):245-53. PubMed ID: 3023555
    [Abstract] [Full Text] [Related]

  • 13. Acute hemodynamic and hormonal effects of MK-521 in congestive heart failure.
    Dickstein K, Aarsland T, Woie L, Kremer D, Abrahamsen AM.
    Scand J Urol Nephrol Suppl; 1984 Sep; 79():125-7. PubMed ID: 6089311
    [Abstract] [Full Text] [Related]

  • 14. Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo.
    Gross DM, Sweet CS, Ulm EH, Backlund EP, Morris AA, Weitz D, Bohn DL, Wenger HC, Vassil TC, Stone CA.
    J Pharmacol Exp Ther; 1981 Mar; 216(3):552-7. PubMed ID: 6259322
    [Abstract] [Full Text] [Related]

  • 15. A discrepancy between the effects of a single oral dose of captopril on blood pressure, plasma renin activity, and serum angiotensin-converting enzyme levels.
    Lechi A, Covi G, Capuzzo MG, Lechi C, Minuz P, Delva P, Scuro LA.
    Int J Clin Pharmacol Ther Toxicol; 1983 Nov; 21(11):569-74. PubMed ID: 6317579
    [Abstract] [Full Text] [Related]

  • 16. Clinical pharmacology of enalapril.
    Abrams WB, Davies RO, Gomez HJ.
    J Hypertens Suppl; 1984 Dec; 2(2):S31-6. PubMed ID: 6100874
    [Abstract] [Full Text] [Related]

  • 17. Plasma enalapril levels and hormonal effects after short- and long-term administration in essential hypertension.
    Johnston CI, Jackson BJ, Larmour I, Cubella R, Casley D.
    Br J Clin Pharmacol; 1984 Dec; 18 Suppl 2(Suppl 2):233S-239S, 241S. PubMed ID: 6099738
    [Abstract] [Full Text] [Related]

  • 18. Effects of enalapril, a new converting enzyme inhibitor, in hypertension.
    Ferguson RK, Vlasses PH, Swanson BN, Mojaverian P, Hichens M, Irvin JD, Huber PB.
    Clin Pharmacol Ther; 1982 Jul; 32(1):48-53. PubMed ID: 6282527
    [Abstract] [Full Text] [Related]

  • 19. Effects of captopril and enalapril on sodium excretion and blood pressure in sodium-deficient dogs.
    McCaa RE, Gillespie JB.
    Fed Proc; 1984 Apr; 43(5):1336-41. PubMed ID: 6323226
    [Abstract] [Full Text] [Related]

  • 20. Enalapril and atenolol in primary hypertension--a comparative study of blood pressure lowering and hormonal effects.
    Ohman KP, Karlberg BE.
    Scand J Urol Nephrol Suppl; 1984 Apr; 79():93-7. PubMed ID: 6089325
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.